Ticker Symbol: FENC
Fennec Pharmaceuticals Inc
$9.71 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001211583
Company Profile
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: PO Box 13628
Website: http://fennecpharma.com/
CEO: Rostislav Raykov
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $7.03
Change:
-$0.10
(
-1.40%)
Days Range: $6.83 - $7.10
Beta: 0.64
52wk. High: $10.85
52wk. Low: $6.30
Ytd. Change -27.13%
50 Day Moving Average: $7.37
200 Day Moving Average: $8.09
Shares Outstanding: 26632950
Valuation
Market Cap: 18.7B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A